Clinical Trial Updates

Two-Drug HIV Tablet Versus Standard First-Line Regimen in Phase 3 Trial

George Padron
Specialty Medicine, ID & Vaccines, Clinical Trial Updates | Jul 10, 2026
A phase 3 trial finds the two-drug doravirine-islatravir tablet noninferior to bictegravir-emtricitabine-tenofovir for initial HIV-1 treatment at 48 weeks.

Head-to-Head Trial Compares Low-Cost MS Drug to Brand Drug

George Padron
Neurology & Mental Health, Multiple Sclerosis, Clinical Trial Updates | Jul 8, 2026
OVERLORD-MS, the first randomized head-to-head trial, finds low-cost off-label rituximab noninferior to ocrelizumab on MRI activity in newly diagnosed relapsing MS.

GLP-1 Drug Coverage for Type 1 Diabetes

Sonia Reyes
Cardiology, Endocrinology & Metabolic, Clinical Trial Updates | Jul 7, 2026
An emulated-trial study of 174,678 adults with type 1 diabetes links GLP-1 receptor agonist use to lower risks of major cardiac events and kidney failure.